scholarly journals A Case of Hyperintense Liver Metastases of Breast Cancer in the Hepatobiliary Phase on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging

2020 ◽  
Vol 13 (2) ◽  
pp. 973-978
Author(s):  
Tomoyuki Yamaguchi ◽  
Shoji Oura ◽  
Mariko Honda ◽  
Shinichiro Makimoto
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Abdominal Pain ◽  
Magnetic Resonance ◽  
Liver Metastases ◽  
Histological Examination ◽  
Gadoxetic Acid ◽  
Hepatobiliary Phase ◽  
Resonance Imaging ◽  
Enhanced Mri

A 64-year-old woman complaining of left arm and breast edema was referred to our hospital. Mammography and ultrasound could not initially show any masses, but magnetic resonance imaging (MRI) showed ill-defined small masses in her left breast. Histological examination showed the tumor to be triple-negative breast cancer. After neoadjuvant chemotherapy, the patient underwent operation. Postoperative histological examination showed massive cancer remnants in the lymph nodes and lymphatics. Enhanced CT taken at the onset of abdominal pain showed multiple liver masses with ring enhancement 17 months after the operation. Gadoxetic acid-enhanced MRI showed hyperintense masses and presumed broad cancer cell permeation to the liver in the hepatobiliary phase. Due to the histologically proven high lymphatic permeability, metastatic sites, and gadoxetic acid-enhanced MRI findings, we judged the liver metastases as lymphatic liver metastases. Due to the marked liver dysfunction at the onset of abdominal pain, the patient received best supportive care and died in 4 months.

scholarly journals The possibility of applying magnetic resonance imaging with hepatospecific contrast agent.

2018 ◽  
Vol 96 (3) ◽  
pp. 213-221
Author(s):  
Karina K. Lomovtseva ◽  
G. G. Karmazanovsky
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agent ◽  
Gadoxetic Acid ◽  
Focal Liver Lesions ◽  
Hepatobiliary Phase ◽  
Liver Lesions ◽  
Resonance Imaging ◽  
Cross Sectional ◽  
Extracellular Contrast Agent

Nowadays, it is difficult to overestimate the role of cross-sectional imaging in the diagnosis of focal and diffuse liver diseases. In magnetic resonance imaging (MRI) there is a unique opportunity to use hepatospecific contrast agents compared with other visualization techniques. Gadoxetic acid is a hepatospecific magnetic resonance contrast agent which has the extracellular contrast agent properties and hepatotropic property. About half of the administered dose of gadoxetic acid enters into functioning hepatocytes through cell membrane transporters and then is excreted into the bile ducts and sinusoidal space. The obtained hepatobiliary phase provides information about the structural features of the focal liver lesions, improving their detection and differential diagnosis. In addition it allows to assess the anatomical and functional conditions of the hepatobiliary system. This article describes clinical applications of MRI with gadoxetic acid and its benefits, visualization principles of different focal liver lesions in hepatobiliary phase and features of the obtained images.

scholarly journals Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging

2021 ◽  
Author(s):  
Dow-Mu Koh ◽  
Ahmed Ba-Ssalamah ◽  
Giuseppe Brancatelli ◽  
Ghaneh Fananapazir ◽  
M. Isabel Fiel ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Liver Disease ◽  
Magnetic Resonance ◽  
Gadoxetic Acid ◽  
Resonance Imaging ◽  
International Forum ◽  
Enhanced Mri ◽  
Consensus Statements ◽  
Liver Magnetic Resonance Imaging ◽  
Enhanced Imaging

Abstract Objectives The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid–enhanced imaging. Methods As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid–enhanced MRI in primary liver cancer and metastatic liver disease. Results and conclusions Gadoxetic acid–enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid–enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid–enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers. Key Points • Gadoxetic acid–enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy. • Gadoxetic acid–enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies. • Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid–enhanced MRI for the assessment of liver and biliary function is under active investigation.

Sign in / Sign up

Export Citation Format

Share Document